Biotech platform company Alteogen reported record quarterly sales for Q1 2025, with revenue of 83.7 billion won, operating profit of 61 billion won, and net profit of 83 billion won. This performance was driven by the technology export contract fee received from AstraZeneca and product sales from the commercialization of the ALT-B4 substance. Alteogen has exported the development rights for subcutaneous injection form treatments to six global pharmaceutical companies and plans to register the ALT-B4 substance patent in the US this month.
Original Article: Read More
Auto-posted at: 2025-05-14 09:02:25